| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 100mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
Eicosadienoic acid antagonizes the leukotriene B₄ (LTB₄) receptor with an IC₅₀ of 15 μM.[2]
|
|---|---|
| ln Vitro |
Eicosadienoic acid (10–100 μM) inhibits LTB₄-induced chemotaxis in human neutrophils by 60–85%, demonstrating functional blockade of LTB₄ receptor signaling. At 30 μM, it reduces LTB₄ binding to neutrophil membranes by 50%, confirming direct receptor antagonism.[2]
In LPS-stimulated murine macrophages (RAW 264.7 cells), eicosadienoic acid (50 μM, 24 hr) differentially modulates inflammatory mediators: suppresses TNF-α (~40%) and IL-6 (~50%) production while increasing anti-inflammatory IL-10 (~2-fold). Concurrently inhibits iNOS expression and NO production (~60% reduction), and reduces PGE₂ synthesis (~40%).[1] At a Ki of 3 µM, eicosadienoic acid prevents [3H]-LTB4 from attaching to pig neutrophil membranes[2]. |
| Enzyme Assay |
LTB₄ Receptor Binding: Human neutrophil membranes were incubated with ³H-LTB₄ (1 nM) and increasing concentrations of eicosadienoic acid (1–100 μM) for 30 min at 4°C. Bound radioactivity was quantified after filtration through glass fiber filters.[2]
|
| Cell Assay |
Neutrophil Chemotaxis: Human neutrophils were pre-incubated with eicosadienoic acid (10–100 μM) for 10 min at 37°C, then placed in Boyden chambers. LTB₄ (10 nM)-directed migration was measured after 45 min incubation.[2]
Macrophage Cytokine Profiling: RAW 264.7 cells were pretreated with eicosadienoic acid (50 μM) for 1 hr, followed by LPS (1 μg/mL) stimulation for 24 hr. Cytokines (TNF-α, IL-6, IL-10) in supernatants were analyzed by ELISA; NO by Griess reaction; PGE₂ by enzyme immunoassay; iNOS expression by Western blot.[1] |
| References | |
| Additional Infomation |
Eicosapentaenoic acid (EPA) is a long-chain fatty acid.
Eicosapentaenoic acid is a polyunsaturated long-chain fatty acid with a 20-carbon backbone and two double bonds. There are at least five different isomers that can be called EPA. Eicosapentaenoic acid (especially the 11(Z),14(Z)-isomer) is an essential ω-6 fatty acid that competitively inhibits the binding of LTB₄ to its receptor on neutrophils, thereby disrupting chemotaxis, suggesting that it has an anti-inflammatory mechanism. [2] Its bidirectional regulation of pro-inflammatory and anti-inflammatory mediators in macrophages suggests that it has an environment-dependent immunomodulatory function, which may be applicable to inflammation-related diseases. [1] |
| Molecular Formula |
C20H36O2
|
|---|---|
| Molecular Weight |
308.49864
|
| Exact Mass |
308.271
|
| CAS # |
2091-39-6
|
| Related CAS # |
5598-38-9
|
| PubChem CID |
5282805
|
| Appearance |
Colorless to light yellow liquid（Density：0.905±0.06 g/cm3）
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
462.1±0.0 °C at 760 mmHg
|
| Flash Point |
326.3±15.2 °C
|
| Vapour Pressure |
0.0±2.4 mmHg at 25°C
|
| Index of Refraction |
1.478
|
| LogP |
8.24
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
22
|
| Complexity |
292
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCC/C=C/C/C=C/CCCCCCCCCC(O)=O
|
| InChi Key |
XSXIVVZCUAHUJO-AVQMFFATSA-N
|
| InChi Code |
InChI=1S/C20H36O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10H,2-5,8,11-19H2,1H3,(H,21,22)/b7-6+,10-9+
|
| Chemical Name |
(11E,14E)-icosa-11,14-dienoic acid
|
| Synonyms |
11,14-Eicosadienoic acid; 2091-39-6; 11, 14-icosadienoic acid; C20:2n-6,9; 11,14-trans-Eicosadienoic acid; DTXSID101312766; n-6 eicosadienoic acid; delta11,14-20:2;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~324.15 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.10 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.10 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.10 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2415 mL | 16.2075 mL | 32.4149 mL | |
| 5 mM | 0.6483 mL | 3.2415 mL | 6.4830 mL | |
| 10 mM | 0.3241 mL | 1.6207 mL | 3.2415 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
